Economic Situation

Debate between Siobhain McDonagh and Chris Philp

Wednesday 12th October 2022 Commons Chamber

[Chris Philp]

I thank my hon. Friend for his question. It obviously depends on the prices at which the Bank and England buys and sells bonds or gilts in the market. It is worth observing that so far it has purchased considerably less by value of gilts than the limits that were set out originally. The volume of gilts that it has on its balance sheet is much less than the limits. On his question about fiscal cost, if there is any fiscal cost, that will depend entirely on market prices.

[Siobhain McDonagh (Mitcham and Morden) (Lab)]

Two days before the Budget, a young constituent of mine hoped to buy her home through shared ownership. She was offered a mortgage at 4.28% interest by the Halifax. A day after the statement, the offer was withdrawn and a two-year fixed-rate deal has rocketed to 6.9%—that is £150 a month more overnight because of the Government’s unfunded giveaways to people on over 150 grand a year. What is the Minister’s advice to my constituent? Should she take the deal, or does he agree with the panel of experts at the Treasury Committee this morning that she should not go near it, because house prices are about to plummet?

[Chris Philp]

I am obviously not going to offer individual financial advice to constituents. What I would say is that there are about 2,300 mortgage products currently on the market. We are keen as a Government to help first-time buyers, particularly younger ones in their 20s and 30s, which is why stamp duty is being cut for cheaper purchases. The stamp duty threshold for first-buyers has been raised, from memory, to £425,000, which particularly helps with putting together a deposit, which cannot be mortgage-funded. In addition, we want to help people with the broader cost of living pressures, which makes it easier to find money to fund mortgages. That is what the energy price guarantee is designed to do, and it is what lower tax rates in general are designed to do, including the tax reductions that the Labour party voted for yesterday. It is what the cost of living package is designed to do—the £37 billion. By helping with the cost of living in general, we are obviously making mortgage costs a little easier to meet.

No Recourse to Public Funds

Debate between Siobhain McDonagh and Chris Philp

Thursday 8th October 2020 Westminster Hall

[The Parliamentary Under-Secretary of State for the Home Department (Chris Philp)]

It is a pleasure to serve under your chairmanship, Mr Paisley. I only narrowly avoided serving under the chairmanship of Ms Nokes, one of my predecessors in this role, as several Members have mentioned this afternoon.

I congratulate the right hon. Member for East Ham (Stephen Timms), my hon. Friend the Member for Ruislip, Northwood and Pinner (David Simmonds) and, of course, the hon. Member for Glasgow South West (Chris Stephens) on securing this afternoon’s important debate. Everybody who has spoken has contributed with great sincerity and passion, and I have been listening carefully to everything Members have said. Where I have, occasionally, been on the phone, I have been texting officials asking various questions in follow up on points that have been raised.

I will start by laying out some of the historical context to the “no recourse to public funds” policy. It has existed since the Immigration Act 1971, and the principle that underpins it is that it would not be reasonable for people who have arrived here very recently or on a temporary basis to be able to access the full range of benefits available to somebody who is settled here or a citizen. If we look at the categories of people to whom the NRPF condition applies, it is people such as visitors, those who are here on a holiday visa, students, people who come here to study, and workers who are here for a short time or, in some cases, a longer time. There would be an inherent unfairness if, having literally just arrived, people were able to fully access public funds.

[Siobhain McDonagh]

Can the Minister add to his list women whose children are born and brought up here and are UK citizens, and are going nowhere?

[Chris Philp]

I was going to come to that point. It is a very reasonable question to raise. Let me just finish my point, and I will come on to address the point that the hon. Lady has raised, entirely understandably and rightly.

It is worth mentioning that, of course, refugees are not subject to the NRPF condition. A couple of hon. Members, including the hon. Member for Birmingham, Selly Oak (Steve McCabe), talked about the time it takes to make decisions. I am not sure if he was referring to asylum decisions or another kind of decision, but I make it clear that anyone claiming asylum or anyone granted asylum is not subject to the NRPF condition, and neither are people who are granted indefinite leave to remain.

Breast Cancer Drugs

Debate between Siobhain McDonagh and Chris Philp

Thursday 26th January 2017 Commons Chamber

[Siobhain McDonagh]

I agree with my hon. Friend. It is amazing to think that, for this particular drug, it will take longer to get overall survival data because people are living longer without their cancer spreading. That obvious success is seen as a big disadvantage in the NICE appraisal system. The cost of Palbociclib will appear to be much higher in the NICE formula because overall survival data are given much more weight than progression-free survival. That seems illogical to me.

Consider also the criteria for determining end-of-life treatment. If a treatment is end-of-life, it is allowed double the quality-adjusted life year costings of other drugs. End-of-life is considered to be two years, but why not three? How have we ended up with such an arbitrary, fixed figure, especially when the figure in Scotland is three years? There is no cure for secondary breast cancer, but as people start to live longer it will place them at a disadvantage when accessing treatments, because it will be harder for those treatments to become approved, as they are no longer considered under the end-of-life criteria.

Therefore, how can the Minister be sure that the NICE process is still fit for purpose? Will she respond specifically on two suggestions: first, to review the weighting for progression-free survival when overall survival is not available because a treatment is so effective; and secondly, to change the criteria for end-of-life treatment to three years’ survival instead of two?

I want to return to the issue of off-patent treatments. In recent years there have been two private Members’ Bills on the topic, one of which was introduced by my hon. Friend the Member for Torfaen (Nick Thomas-Symonds). We heard many commitments from the then Minister for Life Sciences, but we have not yet seen any improvement in access, which is hugely disappointing. The Minister committed to establishing a working group to investigate what could be done to enable the routine use of such treatments. I believe that the working group is due to conclude its work next month and publish its report. Will the report introduce a clear pathway for off-patent treatments, and will the Minister write to me with the details of the pathway and state explicitly how it will work for bisphosphonate drugs for the prevention of secondary breast cancer?

Breast Cancer Now and others have been disappointed by the extremely patchy availability of this treatment for eligible women. As a result, it recently launched the “43p a day” campaign to highlight the low cost of the treatment and the fact that it would save over 1,000 lives every year in the UK if it was routinely available, not to mention millions of pounds for the NHS.

[Chris Philp (Croydon South) (Con)]

I congratulate the hon. Lady on securing the debate. I want to put on the record my support for the case she is making and draw the House’s attention to the case of my constituent Bonnie Fox—she is in the Gallery today—who is suffering in the way the hon. Lady has described, and whose life chances would be greatly improved if something more could be done to preserve the availability of Kadcyla. I once again express my support for the case the hon. Lady is so eloquently making.

[Siobhain McDonagh]

I thank the hon. Gentleman. He is very lucky to have a constituent as exceptional as Bonnie Fox, who has already been mentioned because of all her work.

As a result of Breast Cancer Now’s campaign, the Minister has said that clinical commissioning groups are responsible for commissioning the treatment for bisphosphonates. What contact has been made with CCGs on the use of this treatment in these circumstances? As I understand it, the treatment presents a challenge to existing commissioning arrangements because it does not fit squarely into either specialised services, which are commissioned by NHS England, or local commissioning by CCGs. Does the Minister agree that if we want genuine progress on the availability of this treatment, we cannot take the path of least resistance and just say, “It’s up to CCGs; CCGs are independent bodies and can make their own decisions.” That is the “do nothing” option.

Treatments do not always fit into the neat categories that we create. This is an old treatment that requires a new approach. It requires our commissioning strategists at NHS England to make a considered decision about how to commission the treatment routinely. Will the Minister agree to meet Ian Dodge, the national director for commissioning strategy, to discuss this specific case with him and will she keep Members here today updated on those discussions? Will she also agree that it is indeed worrying that a treatment that could prevent over 1,000 women getting secondary breast cancer every year is not routinely available?

Finally—I think that everybody will be delighted that I am about to finish—I hope that the Minister will consider meeting some of the women affected by the decision on Kadcyla and the women from Breast Cancer Now who are here today. I would like to thank those women in the Public Gallery for coming here to show their support for this debate en masse. I wish every single one of them well. Access to life-enhancing and life-saving drugs should be a right in the UK, not a decision based on a lottery of access to private healthcare. I sincerely hope that NICE will reverse its decision and give every woman with secondary breast cancer their future back.

Affordable Housing (London)

Debate between Siobhain McDonagh and Chris Philp

Wednesday 9th September 2015 Westminster Hall

[Chris Philp]

On affordability, basic economics dictate that as we increase supply relative to demand, prices will fall, so irrespective of tenure types, controlled rents and so on, increasing supply will tend to help affordability.

[Siobhain McDonagh (Mitcham and Morden) (Lab)]

Will the hon. Gentleman address the point that in a capital city the demand is not only from people who live here, but from international developers, who see housing as a good investment? We could increase supply, but none of our communities would be able to muscle their way into getting some of those properties.

[Chris Philp]

Let me take the latter point made by the right hon. Member for Tottenham (Mr Lammy) before coming on to the hon. Lady’s. On affordability, supply and demand clearly drive prices. I am delighted that under the current Mayor of London we have delivered 3,000 council houses, whereas under the previous Mayor virtually none were delivered. Taken together, the number of housing association starts and local authority starts under this Government is 5% higher than under the Labour Government.